Cargando…
Characterization and dynamics of specific T cells against nucleophosmin-1 (NPM1)-mutated peptides in patients with NPM1-mutated acute myeloid leukemia
Nucleophosmin(NPM1)-mutated protein, a leukemia-specific antigen, represents an ideal target for AML immunotherapy. We investigated the dynamics of NPM1-mutated-specific T cells on PB and BM samples, collected from 31 adult NPM1-mutated AML patients throughout the disease course, and stimulated with...
Autores principales: | Forghieri, Fabio, Riva, Giovanni, Lagreca, Ivana, Barozzi, Patrizia, Vallerini, Daniela, Morselli, Monica, Paolini, Ambra, Bresciani, Paola, Colaci, Elisabetta, Maccaferri, Monica, Gilioli, Andrea, Nasillo, Vincenzo, Messerotti, Andrea, Pioli, Valeria, Arletti, Laura, Giusti, Davide, Bettelli, Francesca, Celli, Melania, Donatelli, Francesca, Corradini, Giorgia, Basso, Sabrina, Gurrado, Antonella, Cellini, Monica, Trenti, Tommaso, Marasca, Roberto, Narni, Franco, Martelli, Maria Paola, Falini, Brunangelo, Potenza, Leonardo, Luppi, Mario, Comoli, Patrizia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368236/ https://www.ncbi.nlm.nih.gov/pubmed/30783516 http://dx.doi.org/10.18632/oncotarget.26617 |
Ejemplares similares
-
Neoantigen-Specific T-Cell Immune Responses: The Paradigm of NPM1-Mutated Acute Myeloid Leukemia
por: Forghieri, Fabio, et al.
Publicado: (2021) -
NPM1-Mutated Myeloid Neoplasms with <20% Blasts: A Really Distinct Clinico-Pathologic Entity?
por: Forghieri, Fabio, et al.
Publicado: (2020) -
All‐trans retinoic acid (ATRA) in non‐promyelocytic acute myeloid leukemia (AML): results of combination of ATRA with low‐dose Ara‐C in three elderly patients with NPM1‐mutated AML unfit for intensive chemotherapy and review of the literature
por: Forghieri, Fabio, et al.
Publicado: (2016) -
Minimal/Measurable Residual Disease Monitoring in NPM1-Mutated Acute Myeloid Leukemia: A Clinical Viewpoint and Perspectives
por: Forghieri, Fabio, et al.
Publicado: (2018) -
Preclinical Validation of an Advanced Therapy Medicinal Product Based on Cytotoxic T Lymphocytes Specific for Mutated Nucleophosmin (NPM1(mut)) for the Treatment of NPM1(mut)-Acute Myeloid Leukemia
por: De Cicco, Marica, et al.
Publicado: (2023)